284 related articles for article (PubMed ID: 9400444)
21. Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder.
Turan T; Efiloğlu Ö; Günaydin B; Özkanli Ş; Nikerel E; Atiş G; Çaşkurlu T; Yildirim A
Int Braz J Urol; 2018; 44(2):267-272. PubMed ID: 29219283
[TBL] [Abstract][Full Text] [Related]
22. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
23. Multiple adverse histological features increase the odds of under staging T1 bladder cancer.
Weizer AZ; Wasco MJ; Wang R; Daignault S; Lee CT; Shah RB
J Urol; 2009 Jul; 182(1):59-65; discussion 65. PubMed ID: 19447443
[TBL] [Abstract][Full Text] [Related]
24. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.
Orsola A; Werner L; de Torres I; Martin-Doyle W; Raventos CX; Lozano F; Mullane SA; Leow JJ; Barletta JA; Bellmunt J; Morote J
Br J Cancer; 2015 Feb; 112(3):468-74. PubMed ID: 25535728
[TBL] [Abstract][Full Text] [Related]
25. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.
Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P
J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345
[TBL] [Abstract][Full Text] [Related]
26. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
27. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma.
Pagano F; Garbeglio A; Milani C; Bassi P; Pegoraro V
Eur Urol; 1987; 13(3):145-9. PubMed ID: 3609087
[TBL] [Abstract][Full Text] [Related]
29. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
[TBL] [Abstract][Full Text] [Related]
31. Grade 3 bladder cancer with lamina propria invasion (pT1): characteristics of tumor and clinical course.
Takashi M; Sakata T; Murase T; Hamajima N; Miyake K
Nagoya J Med Sci; 1991 Mar; 53(1-4):1-8. PubMed ID: 1805133
[TBL] [Abstract][Full Text] [Related]
32. Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.
Fransen van de Putte EE; Otto W; Hartmann A; Bertz S; Mayr R; Bründl J; Breyer J; Manach Q; Compérat EM; Boormans JL; Bosschieter J; Jewett MAS; Stoehr R; van Leenders GJLH; Nieuwenhuijzen JA; Zlotta AR; Hendricksen K; Rouprêt M; Burger M; van der Kwast TH; van Rhijn BWG
Urol Oncol; 2018 Aug; 36(8):361.e7-361.e13. PubMed ID: 29880460
[TBL] [Abstract][Full Text] [Related]
33. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
34. Surgically treated transitional cell carcinomas of the bladder. The role of radical surgery.
Al-Ali MA; Kashmoula DM; Haddad LF
Saudi Med J; 2002 Jun; 23(6):695-9. PubMed ID: 12070550
[TBL] [Abstract][Full Text] [Related]
35. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion.
Esrig D; Freeman JA; Elmajian DA; Stein JP; Chen SC; Groshen S; Simoneau A; Skinner EC; Lieskovsky G; Boyd SD; Cote RJ; Skinner DG
J Urol; 1996 Sep; 156(3):1071-6. PubMed ID: 8709310
[TBL] [Abstract][Full Text] [Related]
36. Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.
Leivo MZ; Sahoo D; Hamilton Z; Mirsadraei L; Shabaik A; Parsons JK; Kader AK; Derweesh I; Kane C; Hansel DE
Am J Surg Pathol; 2018 Jan; 42(1):e1-e10. PubMed ID: 29076872
[TBL] [Abstract][Full Text] [Related]
37. p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?
Steiner G; Bierhoff E; Schmidt D; Leissner J; Wolf HK; Albers P
Eur J Cancer; 2000 Mar; 36(5):610-4. PubMed ID: 10738125
[TBL] [Abstract][Full Text] [Related]
38. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis.
Inagaki T; Ebisuno S; Uekado Y; Hirano A; Hiroi A; Shinka T; Ohkawa T
Int J Urol; 1997 Mar; 4(2):172-7. PubMed ID: 9179692
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
40. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
